PP
BIVV

Paloma Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Paloma Partners’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,500
Closed -$933K – 2667
2017
Q2 		$933K Buy
+15,500
New +$883K 0.01% 1239

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Paloma Partners's BIVV Position: Q4 2017 in Review

Paloma Partners sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 4,533 shares — an estimated $259K sold.

Paloma Partners first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $290K in Q1 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Paloma Partners reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Paloma Partners sold 4,533 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $259K.
  • Paloma Partners first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Paloma Partners's Bioverativ Inc. Common Stock position peaked at $290K in Q1 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Paloma Partners's 13F filing for Q4 2017, filed 14 Feb 2018.